Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2018

View Archived Issues

Jeil Pharmaceutical begins phase I trial of oral JP-1366

Retrophin and Censa Pharmaceuticals to collaborate on CNSA-001 for PKU

Horizon Pharma licenses MEDI-4945 from MedImmune

Appili Therapeutics obtains rights to F. tularensis vaccine

Cypralis gains exclusive rights to certain cyprolides from Gilead collaboration

Idorsia describes discovery and structure of T-type calcium channel blocker ACT-709478

Caladrius studies CLBS-12 in patients with critical limb ischemia

Phase I study explores use of iC9-CAR19 in relapsed or refractory ALL

Patient enrollment ongoing in phase I trial of TTC-352 for breast cancer

Latest follow-up data from phase Ia trial of ProscaVax

KA34 to enter clinical testing for the treatment of osteoarthritis

Collegium Pharmaceutical enters agreement to commercialize Nucynta in U.S.

FDA gives orphan drug status to Avadel's FT-218 for narcolepsy

Stem cell-derived CAR T-cells persist in simian/human immunodeficiency virus model

MedDay Pharmaceuticals reviews pipeline at J.P. Morgan meeting

Twelve-month interim data show sustained IOP reduction with Glaukos' iDose travoprost

Shionogi and PharmaIN establish research collaboration

Phase I study of AlphaMedix begins in U.S.

Skin organoids derived from pluripotent stem cells display hair folliculogenesis

Sublingual allergy immunotherapy tablet Odactra now available in U.S.

Nagoya City University, University of Tokyo patent mutant SOD1/derlin-1 interaction inhibitors

FDA grants orphan status to eflornithine/sulindac combination for pancreatic cancer

Novel estrogen receptor modulators identified at Roche and Genentech

AstraZeneca's Fasenra approved in E.U.

Bristol-Myers Squibb discovers apelin receptor agonists

Incyte discloses novel PD-1/PD-L1 interaction inhibitors

Merck & Co. presents new histone deacetylase 6 inhibitors

Ferring and Chinese Academy of Sciences announce collaboration in reproductive medicine

Applied Genetic Technologies opens phase I/II study of AGTC-501 in X-linked retinitis pigmentosa

Galapagos obtains rights to MALT1 inhibitors for inflammatory and/or oncological diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.